Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

GLP-1 Users' diets under the microscope: what are they really eating?

NCT ID NCT07313384

Knowledge-focused Sponsor: University of South Carolina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study follows 50 adults who are about to start GLP-1 therapy for obesity or type 2 diabetes. Researchers will track how their eating habits change over 12 weeks using diet quality scores and body weight. The goal is to understand what dietary support people need while on these medications, since current guidance focuses mostly on cutting calories rather than ensuring good nutrition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 therapy (a class of medications for obesity or type 2 diabetes)
What this could lead to
If successful, this study could help develop better dietary guidelines and support programs for people taking GLP-1 medications.
What could go wrong
This is a small observational study (50 people) that does not test a new treatment. It only looks at eating habits, so it cannot prove whether any diet changes improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The recruitment will be conducted at the Prisma Health Weight Management Institute in Greenville, South Carolina, with support from the on-site research team. A total of 50 patients will be enrolled. Eligible individuals will be adults aged 18 years or older who have recently been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 and older * Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication * Has regular access to a smartphone and internet to complete short surveys and food recalls online * Willing to sign informed consent. Exclusion Criteria: * Already began the GLP-1 medication * Have medical concerns making participation unsafe

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity (disorder) Obesity type 2 diabetes mellitus

Contacts and locations

Locations

  • Prisma Health Weight Management Institute

    Greenville, South Carolina, 29607, United States

  • University South Carolina

    Columbia, South Carolina, 20208, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.